TransMedics (TMDX) Q4 2025 earnings review
Top-Line Growth Persists, But Operating Leverage Reverses
TransMedics delivered another quarter of strong top-line growth, with Q4 revenue up 32% YoY to $160.8M, bringing FY25 revenue to $605.5M (+37% YoY). However, the headline Net Income of $105.4M is heavily distorted by an $83.8M one-time tax valuation allowance release. Stripping out the tax noise reveals a concerning trend: pre-tax income fell sequentially for the second straight quarter, landing at $21.6M. Operating margins, which peaked at 23.3% in 25Q2, have severely compressed to 13.2% in 25Q4 due to rising freight, clinical service costs, and R&D investments. While the company's strategic moat (22 owned aircraft and an expanding National OCS Program) is formidable, the transition from hyper-growth to mature scaling is pressuring core profitability.
🐂 Bull Case
FDA approval for the OCS ENHANCE Heart and DENOVO Lung trials opens the door for revenue-generating clinical volumes. This will actively expand TransMedics' TAM into standard criteria DBD hearts and reinvigorate the stagnant lung segment.
The aviation fleet hit 22 owned aircraft at year-end, successfully internalizing the vast majority of transplant logistics. This vertical integration is a massive competitive advantage that rivals simply cannot replicate.
🐻 Bear Case
Despite Q4 revenue being the highest of the year, Operating Income ($21.3M) was the lowest of the last three quarters, indicating that the costs of scaling the NOP network and expanding R&D are currently outpacing incremental revenue gains.
YoY Revenue growth has steadily decelerated from 50% in 24Q4 to 32% in 25Q4. FY26 guidance projects 20-25% growth, confirming that the easiest market share gains have been captured.
⚖️ Verdict: ⚪
Neutral. The operational thesis is fully intact and the company maintains an iron grip on the transplant market. However, reversing operating leverage and decelerating top-line growth suggest the stock may need to consolidate as management digests the costs of its massive infrastructure buildout.
Key Themes
GAAP Earnings Mirage
A massive contradiction to the positive headline earnings emerged this quarter. TransMedics reported $105.4M in Q4 Net Income (up from $24.3M in Q3). However, this was driven almost entirely by an $83.8M one-time tax benefit (release of valuation allowance). Looking at actual operations, Pre-Tax Income was $21.6M, down sequentially from $23.3M in Q3 and $36.6M in Q2. Investors must not mistake the tax-driven EPS beat for underlying operational leverage.
Gross Margin Dilution & OpEx Ramp
Gross margin decelerated to 58% in Q4 (vs 59% in 24Q4 and 61% in 25H1). Management cited higher clinical service expenses in support of NOP expansion and elevated freight costs. Concurrently, Operating Expenses accelerated to $72.1M (up from $61.2M in Q3), fueled by heavy R&D investments and organizational scaling. This combination is actively crushing operating margins.
Top-Line Deceleration
Growth is inevitably decelerating as the base gets larger. YoY Revenue growth has printed a clear downward staircase: 50% -> 48% -> 38% -> 32% -> 32%. FY26 guidance implies a further deceleration to 22.5% at the midpoint. While still a hyper-growth profile, the market will increasingly scrutinize bottom-line conversion as top-line percentage growth slows.
Imminent Clinical Program Launches
Securing FDA approval for the OCS ENHANCE Heart and DENOVO Lung trials is a critical milestone. These trials are not just for R&D; they are revenue-generating programs designed to massively expand the Total Addressable Market by proving superiority in standard criteria (DBD) hearts and reinvigorating the dormant lung transplant segment.
Logistics Fleet Scale Reached
The company hit its target of 22 owned aircraft by the end of 2025. This vertically integrated logistics network drove Q4 Service Revenue to $60.4M (+29% YoY). With the capital expenditure phase largely complete for this initial fleet, management's focus will pivot to 'double shifting' pilots and sweating these assets to eventually drive service gross margin recovery.
OCS Kidney Platform Development
Specific product innovation continues with the OCS Kidney program, scheduled for clinical launch preparation in 2026. Because kidney transplants represent the largest volume of organ transplants globally, successful commercialization of this device would dramatically alter the company's long-term revenue ceiling.
Insulated Macro Dynamics but Seasonal Vulnerability
While management previously noted that organ transplantation is largely insulated from macroeconomic cycles and interest rate pressures, the company is becoming highly sensitive to market seasonality. As TransMedics captures a larger share of the total U.S. transplant market, it inherently absorbs the summer (Q3) and holiday (Q4) volume fluctuations, replacing its previous linear quarter-over-quarter growth narrative.
Other KPIs
Reversing. Down sharply from 23.3% in Q2 and 16.2% in Q3. The $21.3M in operating income is highly disappointing given the $160.8M revenue base, indicating severe negative operating leverage in the second half of the year.
Accelerating volume penetration. A 38% YoY increase from 3,735 cases in FY24, perfectly aligning with the 37% total revenue growth for the year and proving that case volume execution remains flawless.
Stable and strong. Up from $466.2M sequentially, demonstrating that despite the aggressive aircraft purchases earlier in the year and heavy OpEx investments, the company is fundamentally self-funding its growth.
Guidance
Decelerating. The midpoint of $742M implies 22.5% YoY growth, a step down from the 37% growth achieved in FY25. However, this aligns with historical management conservatism and relies primarily on organic U.S. market share expansion, leaving potential upside if the ENHANCE/DENOVO trials enroll faster than expected.
Key Questions
Operating Leverage Timeline
Operating margins compressed severely from 23% in Q2 to 13% in Q4. With the core 22-aircraft fleet now acquired, when do you expect operating leverage to definitively inflect positively again?
Clinical Trial Revenue Contribution
How much revenue from the ENHANCE Heart and DENOVO Lung trials is specifically baked into the FY26 guidance range of $727-$757M?
Gross Margin Stabilization
Given the rising freight costs and NOP expansion expenses cited in Q4, what is the normalized gross margin expectation for FY26 as you begin 'double shifting' the aviation fleet?